Results 171 to 180 of about 12,467 (245)

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review. [PDF]

Front Pediatr
Pietrzykowska A, Darmoń J, Szymocha K, Donocik W, Tarasiewicz M, Stadnik J, Jarosz-Chobot P.   +6 more
europepmc   +1 more source

Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance [PDF]

Gretchen E Bollar, Katherine A. Shaffer, Johnathan D. Keith, Ashley M. Oden, Alexander E. Dowell, Kevin J. Ryan, Edward P. Acosta, Jennifer S. Guimbellot, Megan R. Kiedrowski, Susan E. Birket   +9 more
openalex   +1 more source

WS15.6 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients heterozygous for F508del-CFTR and a residual function mutation

, 2018
Patrick A. Flume, C.A. Owen, Reta Fischer Biner, C Simard, D.G. Downey, Hui Zhou, Julie Lekstrom-Himes, K. De Boeck   +7 more
openalex   +1 more source

Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report. [PDF]

J Pediatr Clin Pract
Piednoir A, Troussier F, Descamps M, Lagarce L, Martin L.   +4 more
europepmc   +1 more source

Improvement of Cystic Fibrosis-Associated Liver Disease in Adults on Long-Term Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. [PDF]

Life (Basel)
Manioudaki S, Vasilieva L, Geladari E, Mani I, Athanassa Z, Elefsiniotis I, Hadziyannis E, Sevastianos V, Oikonomou A, Theophilou A, Diamantea F, Alexopoulou A.   +11 more
europepmc   +1 more source

WS09.3 Increased maximal exercise capacity is associated with increased wellness across the spectrum of age and lung function in adults with cystic fibrosis (CF) after treatment with ivacaftor

, 2016
Brenda Button, Lisa M Wilson, D. Keating, J.W. Wilson   +3 more
openalex   +1 more source

Arterialized oxygen tension and unfavorable clinical outcomes in pediatric cystic fibrosis. [PDF]

Front Pediatr
Gaupmann R, Gruber S, Schmidthaler K, Pauger B, Mersi B, Graf A, Szépfalusi Z, Renner S, Dehlink E.   +8 more
europepmc   +1 more source

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. [PDF]

Clin Transl Sci
Shi A, Agarwal P, Liu ZX, Beringer PM.
europepmc   +1 more source